GREY:TSTIF - Post by User
Post by
echo2on Jan 26, 2018 8:48am
278 Views
Post# 27439088
Scotia Maintains $4.50 Target and OutPerform
Scotia Maintains $4.50 Target and OutPerform Latest Research (26 January 2018)
OUR TAKE: Yesterday, TSO3 hosted an investor event and announced it had renegotiated its distribution arrangement with their commercial partner Getinge. Under the new agreement, TSO3 gains additional sales rights in North America and will now have more control over its destiny. We believe the long-term benefit of having more control over sales should benefit the company. However, in the near term we expect the stock may be challenged to move higher as investors will likely want tangible evidence that this management team can execute the new strategy and that Getinge will extend its agreement beyond 2018. The next potential catalyst for the shares is likely an FDA approval of duodenoscope sterilization in Q1.